Itacitinib adipate (DrugBank: Itacitinib, Adipate)
5 diseases| 告示番号 | 疾患名(ページ内リンク) | 臨床試験数 | 
|---|---|---|
| 46 | 悪性関節リウマチ | 0 | 
| 51 | 全身性強皮症 | 0 | 
| 60 | 再生不良性貧血 | 0 | 
| 97 | 潰瘍性大腸炎 | 0 | 
| 228 | 閉塞性細気管支炎 | 1 | 
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries | 
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04239989 (ClinicalTrials.gov) | December 15, 2020 | 30/12/2019 | Itacitinib for the Treatment of Bronchiolitis Obliterans Syndrome After Donor Hematopoietic Cell Transplant | A Phase I Study to Assess Safety of Selective JAK 1 Inhibitor, Itacitinib, in Patients With Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplant (HCT) | Bronchiolitis Obliterans | Drug: Itacitinib;Drug: Itacitinib Adipate | M.D. Anderson Cancer Center | National Cancer Institute (NCI) | Not yet recruiting | 18 Years | 75 Years | All | 15 | Phase 1 | United States |